Eisai\'s Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan

Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan

TOKYO, Mar 7, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that a marketing authorization application has been submitted in Japan for lemborexant, an investigational agent for sleep-wake r...

More From BioPortfolio on "Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan"